Appetite (Eating) Disorders – Global Clinical Trials Review, 2022
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Appetite Disorders Clinical Trials Market Overview
The global appetite (eating) disorders clinical trials review report H2 2021 provides an overview of appetite disorders clinical trials scenario. This report provides top-line data relating to the clinical trials on eating disorders. The report also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, the report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Additionally, the report provides prominent drugs for in-progress trials (based on the number of ongoing trials).
What are the market dynamics of the global appetite disorders clinical trials market?
The number of eating disorders clinical trials conducted globally, has increased for the period 2017-2020. The average number of patients enrolled was highest in the year 2020. More than 50% of trials have been sponsored by institutions and over 30% by companies.
(Bupropion hydrochloride + naltrexone) ER and mirtazapine alone or in combination have the highest number of ongoing appetite disorders clinical trials.
What are the top regions and countries in the global appetite disorders clinical trials market?
In total, more than 480 clinical trials were conducted on appetite disorders, as of February 2022. Among these trials, over 190 clinical trials were conducted in North America.
Appetite disorders clinical trials market in Asia-Pacific
In the Asia-Pacific region, China has the highest number of eating disorders clinical trials followed by India, Japan, Australia, and South Korea.
Appetite disorders clinical trials market in Europe
Among the European countries, the UK has the highest number of eating disorders clinical trials, followed by Denmark, Germany, Spain, and Sweden.
Appetite disorders clinical trials market in North America
In the country-wise analysis, the US has the highest number of eating disorders clinical trials in North America followed by Canada and Mexico.
Appetite disorders clinical trials market in the Middle East & Africa
Iran has the highest number of eating disorders clinical trials followed by Israel, South Africa and Tanzania.
Appetite disorders clinical trials market in Central & South America
Brazil has the highest number of eating disorders clinical trials in the region.
Appetite disorders clinical trials market in G7 countries
Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of eating disorders to the central nervous system clinical trials as of February 2022. In total, more than 270 clinical trials were conducted on appetite disorders in G7 countries, of which over 170 clinical trials were in the US.
Appetite disorders clinical trials market in E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, India has the highest proportion of eating disorders to central nervous system clinical trials as of February 2022. In total, more than 80 clinical trials were conducted on appetite disorders in E7 Countries, of which over 30 clinical trials were conducted in China.
Global appetite disorders clinical trials market, by region
For more regional insights, download a free report sample
What is the phase-wise outlook of the global appetite disorders therapeutics clinical trials market?
As of February 2022, more than 200 clinical trials were in Phase II, of which over 25 clinical trials were in progress for the period of 1995-2022. During the same period, more than 60 clinical trials were in progress. The trials that were terminated/suspended or withdrawn accounted for more than 60. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
Global appetite disorders clinical trials market, by phase
To know more about key phases, download a free report sample
Who are the key sponsors in the global appetite disorders clinical trials market?
The key sponsors in the eating disorders clinical trials sector are Takeda Pharmaceutical Co Ltd, Tsumura & Co, Insys Therapeutics Inc (Inactive), QPS Holdings LLC, Opiant Pharmaceuticals Inc, Eli Lilly, and Co, Endo International Plc, Humanwell Healthcare Group Co Ltd, Radiant Research Inc, and Sumitomo Chemical Co Ltd.
Global appetite disorders clinical trials market, by key sponsors
To know more about key sponsors, download a free report sample
Market report scope
Key regions | Asia-Pacific, Europe, North America, Middle East & Africa, and Central & South America |
Key sponsors | Takeda Pharmaceutical Co Ltd, Tsumura & Co, Insys Therapeutics Inc (Inactive), QPS Holdings LLC, Opiant Pharmaceuticals Inc, Eli Lilly and Co, Endo International Plc, Humanwell Healthcare Group Co Ltd, Radiant Research Inc, and Sumitomo Chemical Co Ltd. |
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status
- The report reviews top companies involved and enlists all trials (trial title, phase, and status) about the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level
Tsumura & Co
Insys Therapeutics Inc (Inactive)
QPS Holdings LLC
Opiant Pharmaceuticals Inc
Eli Lilly and Co
Endo International Plc
Humanwell Healthcare Group Co Ltd
Radiant Research Inc
Sumitomo Chemical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the global appetite disorders clinical trials market?
The key regions in the global eating disorders therapeutics clinical trials markets are Asia-Pacific, Europe, North America, Middle East & Africa, and Central & South America.
-
Who are the key sponsors in the global appetite disorders clinical trials market?
The key companies in the global eating disorders clinical trials sector are Takeda Pharmaceutical Co Ltd, Tsumura & Co, Insys Therapeutics Inc (Inactive), QPS Holdings LLC, Opiant Pharmaceuticals Inc, Eli Lilly and Co, Endo International Plc, Humanwell Healthcare Group Co Ltd, Radiant Research Inc, and Sumitomo Chemical Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.